Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

NCT00486265 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
47
Enrollment
INDUSTRY
Sponsor class

Stopped AML assess. of response in Part B patients find treatment failure in all 8 evaluable for marrow response following a maximum of 2 induction courses of therapy

Conditions

Interventions

Sponsor

AstraZeneca